- Tesla (TSLA.US) Semi Truck Climbs the Hill After Nine Years of Delays: Factory Establishment Is Just the Beginning, Delivery Challenge Has Only Just Started
- After nine years of delay, Tesla (TSLA.US) Semi finally starts accepting orders for mass production.
- SanDisk drops 8.5% in pre-market trading as earnings and guidance fall short of high expectations
- -- Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q3 Revenue $83.7M, vs. FactSet Est of $83.6M
- BREAKINGVIEWS-Anthropic’s spending is worryingly anthropocentric
- --Earnings Flash (IMO) Imperial Oil Posts Q3 EPS CA$5.11, vs. FactSet Est of CA$4.68
- Knife River Faces Starboard Pressure to Target 22% Adjusted EBITDA Margins by 2029
- Federal Realty Investment Trust's Q3 Core FFO, Revenue Rise
- DONNELLEY FINANCIAL SOLUTIONS, INC. <DFIN.N>: NEEDHAM RAISES TARGET PRICE TO $72 FROM $60
- AbbVie raises profit forecast as immunology drugs continue to drive growth
- BORGWARNER INC. <BWA.N>: MORGAN STANLEY CUTS TARGET PRICE TO $89.00 FROM $95.00
- RIVIAN AUTOMOTIVE, INC. <RIVN.O>: MORGAN STANLEY CUTS TARGET PRICE TO $13.00 FROM $14.00
- ROBLOX CORPORATION <RBLX.N>: MORGAN STANLEY CUTS TARGET PRICE TO $50.00 FROM $55.00
- Pacifica Silver to Start Trading on the OTCQX Best Market
- RBC Raises Price Target on Patterson-UTI Energy to $17 From $15, Keeps Outperform Rating
- Micron Technology falls 5.7% in pre-market trading as Intel's guidance misses expectations
- Nokia drops 5.9% in pre-market trading; option prices are highly volatile, please pay attention to risks.
- ENTEGRIS INC <ENTG.O>: NEEDHAM RAISES TARGET PRICE TO $185 FROM $170
- PINTEREST : STONEX CUTS TARGET PRICE TO $26 FROM $33
- Bernstein raises Starbucks target price to $115
- Deutsche Bank Adjusts Hershey Price Target to $159 From $179, Maintains Hold Rating
- Update: Market Chatter: Nvidia in Talks to Back $30 Billion Nscale Data Center Project for Anthropic
- Canadian National Railway Q3 Adjusted Earnings Rise YoY
- ALLEGRO MICROSYSTEMS, INC. : WELLS FARGO CUTS TARGET PRICE TO $40 FROM $45
- WEC ENERGY GROUP, INC. <WEC.N>: WELLS FARGO RAISES TARGET PRICE TO $129 FROM $127
- PORTLAND GENERAL ELECTRIC COMPANY : WELLS FARGO CUTS TARGET PRICE TO $56 FROM $58
- EDISON INTERNATIONAL <EIX.N>: WELLS FARGO CUTS TARGET PRICE TO $59 FROM $62
- TYLER TECHNOLOGIES, INC. <TYL.N>: WELLS FARGO RAISES TARGET PRICE TO $430 FROM $400
- SANDISK CORP <SNDK.O>: WELLS FARGO CUTS TARGET PRICE TO $1300 FROM $1550
- INTEL CORPORATION <INTC.O>: WELLS FARGO CUTS TARGET PRICE TO $80 FROM $120
- Market Chatter: Exxon Mobil Raises Stake in Mozambique LNG Project to 50%
- RBC Raises Price Target on PTC Therapeutics to $77 From $75, Keeps Sector Perform Rating
- Imperial Oil Declares Fourth-Quarter Dividend of 87 Cents a Share
- Euro Holdings publishes 2026 annual report
- STARBUCKS CORP. <SBUX.O>: MORGAN STANLEY RAISES TARGET PRICE TO $116.00 FROM $115.00
- Royalindo Investa Wijaya Q3 2026 Liabilities Rise 28% on Higher Trade Payables
- ELI LILLY & CO. <LLY.N>: MORGAN STANLEY RAISES TARGET PRICE TO $1596.00 FROM $1430.00
- INTEL CORPORATION <INTC.O>: MORGAN STANLEY CUTS TARGET PRICE TO $75.00 FROM $84.00
- Era Media Sejahtera Total Liabilities Fall 60.67% at End-September
- TECK RESOURCES LTD <TECK.N>: STONEX RAISES TARGET PRICE TO $72 FROM $67
- AMAZON.COM INC : MORGAN STANLEY CUTS TARGET PRICE TO $335.00 FROM $350.00
- Euro Holdings Publishes 2026 Corporate Governance Report
- Imperial Oil 3Q Rev C$16.2B >IMO
- PeterLabs Holdings publishes 2026 annual report
- Imperial Oil 3Q Net C$2.45B >IMO
- Imperial Oil 3Q EPS C$5.11 >IMO
- PeterLabs seeks renewal of share buyback authority for up to 10% of shares
- PeterLabs Holdings Publishes 2026 Corporate Governance Report
- Shield On Service Assets Rise to Rp 1.14 Trillion at End-September
- INTEL <INTC.O>: SUSQUEHANNA CUTS TARGET PRICE TO $75 FROM $105
- AVERY DENNISON CORP : RAYMOND JAMES RAISES TARGET PRICE TO $198 FROM $192
- RIVIAN <RIVN.O>: NEEDHAM CUTS TARGET PRICE TO $18 FROM $23
- Delta Resources Begins Maiden Drilling at I-Zone, Reports Additional Sampling Results at Delta-1 Gold Project
- Piper Sandler Q3 2026 EPS falls 8% year over year to $0.78; Q3 2026 net revenues drop 8% year over year to $443.05 million
- AMAZON : RAYMOND JAMES CUTS TARGET PRICE TO $250 FROM $300
- STRYKER CORPORATION <SYK.N>: NEEDHAM CUTS TARGET PRICE TO $359 FROM $418
- MAPLEBEAR INC. <CART.O>: RAYMOND JAMES CUTS TO MARKET PERFORM FROM OUTPERFORM
- ROBLOX CORPORATION <RBLX.N>: STONEX CUTS TARGET PRICE TO $32 FROM $33
- MERIT MEDICAL SYSTEMS INC <MMSI.O>: NEEDHAM RAISES TARGET PRICE TO $106 FROM $101
- UFP INDUSTRIES, INC. <UFPI.O>: STONEX CUTS TARGET PRICE TO $100 FROM $115
- Banco de Chile Q3 Earnings Fall, Operating Revenue Rises
- FIRST BUSEY CORPORATION <BUSE.O>: RAYMOND JAMES CUTS TO MARKET PERFORM FROM OUTPERFORM
- Reputation Exchange shares remain suspended on Cyprus Stock Exchange's Emerging Companies Market until Dec. 21
- THERMO FISHER SCIENTIFIC INC. <TMO.N>: ARGUS RESEARCH RAISES TARGET PRICE TO $780 FROM $560
- ALPHATEC HOLDINGS, INC. : NEEDHAM CUTS TARGET PRICE TO $12 FROM $14
- AMAZON : STONEX CUTS TARGET PRICE TO $380 FROM $400
- ALNYLAM PHARMACEUTICALS, INC. : RAYMOND JAMES CUTS TO OUTPERFORM FROM STRONG BUY; CUTS TARGET PRICE TO $315 FROM $420
- YNH Property cuts total borrowings 23.3% to RM 409.8 million in FY2026
- GILEAD <GILD.O>: NEEDHAM RAISES TARGET PRICE TO $200 FROM $170
- --LCI Industries Board Rejects Monomoy Capital's $101 per Share Acquisition Bid
- MASTERCARD <MA.N>: ARGUS RESEARCH RAISES TARGET PRICE TO $694 FROM $640
- Sopharma shareholders approve EUR 0.068 per-share dividend at annual meeting
- PRISA Opens Sixth Debt Conversion Period Nov. 1-10, 2026
- AbbVie 3Q Global Rinvoq Revenue $2.71B, Up 23.9% >ABBV
- AbbVie Sees FY Adj EPS $13.95-Adj EPS $13.99 >ABBV
- AbbVie 3Q Global IMBRUVICA Rev $522M >ABBV
- AbbVie 3Q Global Skyrizi Rev $5.78B >ABBV
- AbbVie 3Q Adj EPS $3.82 >ABBV
- AbbVie 3Q U.S. HUMIRA Rev $372M >ABBV
- AbbVie 3Q EPS $2.37 >ABBV
- AbbVie 3Q Rev $17.4B >ABBV
- AbbVie 3Q Adj EPS $3.82 >ABBV
- AbbVie Raises 2026 View To Adj EPS $13.95-Adj EPS $13.99 >ABBV
- AbbVie Had Seen 2026 Adjusted EPS $13.76 - $13.96 >ABBV
- AbbVie Raises Quarterly Dividend to $1.82 From $1.73 >ABBV
- AbbVie 3Q Adjusted Gross Margin 85.1% >ABBV
- AbbVie 3Q Global Net Revenue From Immunology Portfolio $9.165B, Up 16.5% >ABBV
- AbbVie 3Q Global Net Revenue From Neuroscience Portfolio $3.39B, Up 19.4% >ABBV
- AbbVie 3Q Global Net Revenue From Oncology Portfolio $1.7B, Up 0.8% >ABBV
- AbbVie 3Q Global Net Revenue From Aesthetics Portfolio $1.18B, Down 1.4% >ABBV
- AbbVie 3Q Global Humira Revenue $683M, Down 31.2% >ABBV
- AbbVie 3Q EPS $2.37 >ABBV
- AbbVie 3Q Net $4.22B >ABBV
- AbbVie 3Q Global Net Rev From Oncology Portfolio $1.7B >ABBV
- AbbVie 3Q International HUMIRA Rev $311M >ABBV
- AbbVie 3Q Global Skyrizi Revenue $5.78B, Up 22.7% >ABBV
- AbbVie 3Q Global Vraylar Revenue $1.07B, Up 14.3% >ABBV
- AbbVie 3Q Global Botox Therapeutic Revenue $1.08B, Up 9.8% >ABBV
- Allarity Therapeutics Secures First Lab Services Contract With European Biotech Company
- Mammoth Energy Services 3Q EPS 1c >TUSK
